Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Biotechnology

Healthcare
$2.03 +2.84%

+$0.11 today

Market cap
$171.45M
Beta
0.97
P/E (TTM)
-5.5
EPS (TTM)
-$0.70
52W Low $1.35High $4.60

Volume 1.12M

Average 1.37M

ELDN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Eledon Pharmaceuticals, Inc.NASDAQ: ELDN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $17.2M rose 27.1% year over year, ahead of the +20.4% change in trailing-twelve-month research & development. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +34.8% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +27.1% holds above the trailing-twelve-month pace of +20.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.2M-1.7% QoQ
Last fiscal yearDec 2025
$66.27M+27.5% YoY
LTMMar 2026
$69.93M+20.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.1%——
1 year+27.5%——
3-year CAGR+34.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
66.27M USD
Year-over-year change
+27.5%
4-year CAGR
+29.3%

Research & Development vs competitors

How ELDN compares with its peers on the latest reported figures

  • ELDN's LTM Mar 2026 research & development of $69.93M is the 7th highest of the 11 companies compared; the peer median is $87.67M.
  • Its year-over-year change of +20.4% is the 3rd highest of 11, against a peer median of -7.2%.
  • Over three fiscal years its annual growth of +34.8% compares with a peer median of +4.5%.
ELDN Competitors Peer median
Research & Development for ELDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$159.57M +37.4%+18.6%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$143.25M +11.2%+28.8%2496.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M -32.1%-16.3%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$127.75M -3.1%+30.4%350.1%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$101.99M +14.6%+8.4%46.8%
HUMAHumacyte, Inc.LTM Mar 2026$73.35M -11.4%+3.1%3638.2%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$69.93M +20.4%+34.8%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$68M +23.2%+5.9%29.9%
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M -62.3%-19.9%171.1%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$26.43M -28.8%-2.5%181.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$19.19M -29.2%-8.6%—
Peer median (excluding ELDN) $87.67M-7.2%+4.5%181.7%

Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development23.74M27.08M30.31M51.96M66.27M
Selling, General & Admin13.13M12.7M12.69M18.61M16.98M
Operating Expenses36.87M88.43M43M70.58M83.25M
Depreciation & Amortization195K373K374K359K313K
EBITDA(36.67M)(39.41M)(116.16M)(35.39M)(45.27M)
EBITDA Margin—————
Operating Income(36.87M)(88.43M)(43M)(70.58M)(83.25M)
Operating Margin—————
Interest Income00000
Interest Expense00000
Other Income / Expenses7K462K(73.54M)34.82M37.67M
Income Before Tax(36.86M)(87.97M)(116.54M)(35.75M)(45.58M)
Pre-Tax Margin—————
Income Tax Expense(2.35M)00431K35K
Net Income(34.51M)(87.97M)(116.54M)(36.18M)(45.62M)
Net Margin—————
EPS (Basic)(2.33)(6.16)(4.73)(0.75)(0.56)
EPS (Diluted)(2.33)(6.16)(4.73)(0.75)(0.56)
Weighted Avg Shares14.82M14.29M24.62M48.54M81.84M
Weighted Avg Shares (Diluted)14.82M14.29M24.62M48.54M81.84M

Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Intrinsic Alpha fair value

Locked

Current Price

$2.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.